KOD

Kodiak Sciences Inc.

Biological Products, (No Diagnostic Substances) · SIC 2836CIK 1468748Held by 4 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:X LINKEDIN EMAIL

Revenue FY2025

—

Net Income FY2025

$(230.0M)

EPS (Basic, as reported)

$-4.32

Net Margin FY2025

—

ROE FY2025

-146.1%

Total Equity

$157.0M

Shares Out

63M

Business description

Kodiak Sciences Inc. — Biological Products, (No Diagnostic Substances). Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2016–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions

default rows · click any row to chart itNet income: (17) → (230)

Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025

Research & development(14)(22)(19)(38)(107)(217)(268)(206)(126)(182)

General & administrative(3)(3)(8)(12)(29)(50)(74)(71)(61)(52)

Total operating expenses(17)(26)(26)(49)(136)(267)(341)(277)(187)(234)

Operating income(17)(26)(26)(49)(136)(267)(341)(277)(187)(234)

Interest expense0(1)(6)0000000

Interest & investment income—01230717115

Other income (expense), net0(1)(4)00010(1)0

Pre-tax income(17)(28)(41)(47)(133)(267)334260(176)(230)

Income tax expense————000000

Net income(17)(28)(41)(47)(133)(267)(334)(260)(176)(230)

EPS — basic————($2.91)($5.16)($6.39)($4.97)($3.35)($4.32)

EPS — diluted————($2.91)($5.16)($6.39)($4.97)($3.35)($4.32)

Shares outstanding — basic (M)————465252525353

Shares outstanding — diluted (M)————465252525353

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.